TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28706331

Group type: EXPERIMENTAL
Intervention: Branded amoxicillin capsule
Number of subjects: 12

Group type: COMPARATOR
Intervention: Generic amoxicillin capsule
Number of subjects: 12
Study: 24965202

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23986090

Group type: COMPARATOR
Intervention: Erlotinib 150 mg daily (monotherapy)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg during 15 days intercalated with four 21-day cycles of docetaxel or pemetrexed (combination therapy)
Number of subjects: 231
Study: 20659263

Group type: EXPERIMENTAL
Intervention: Levamisole plus vitamin B12
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Vitamin B12 only
Number of subjects: 147

Group type: COMPARATOR
Intervention: Levamisole only
Number of subjects: 147

Group type: COMPARATOR
Intervention: No further vitamin B12 treatment
Number of subjects: 147
Study: 19746240

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (up to 8 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18193690

Group type: EXPERIMENTAL
Intervention: Lidocaine 8 mg sore throat lozenges
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 15175564

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11461055

Group type: EXPERIMENTAL
Intervention: Oarsmen
Number of subjects: 39
Study: 9515666

Group type: EXPERIMENTAL
Intervention: Imipenem 3 x 1.0 g per day
Number of subjects: 192

Group type: COMPARATOR
Intervention: Imipenem 3 x 0.5 g per day
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 192
Study: 7829275

Group type: EXPERIMENTAL
Intervention: Abstinence-oriented program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indefinite methadone maintenance
Number of subjects: 0
Study: 3043367

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 319

Group type: COMPARATOR
Intervention: Whole-cell vaccine
Number of subjects: 319
Study: 30244028

Group type: EXPERIMENTAL
Intervention: Intensified multifactorial treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional multifactorial treatment
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Doubling urine 8‐oxoGuo level
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: High urine 8‐oxoGuo levels
Number of subjects: 160
Study: 27174405

Group type: EXPERIMENTAL
Intervention: Nonsplinted implants with ball attachment (BA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Splinted implants with bar attachment (RA)
Number of subjects: 30
Study: 25531996

Group type: EXPERIMENTAL
Intervention: L. reuteri (DSM 17938)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22442102

Group type: EXPERIMENTAL
Intervention: Automated email-based campaign promoting self-help behaviours
Number of subjects: 1326

Group type: COMPARATOR
Intervention: General information about depression (Control)
Number of subjects: 1326
Study: 21443093

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy with indigo carmine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 130
Study: 17490972

Group type: EXPERIMENTAL
Intervention: Inadequate protein (IP) group; 0.5 g protein x kg(‐1) x d(‐1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group; 1.2 g protein x kg(‐1) x d(‐1)
Number of subjects: 21
Study: 16137086

Group type: EXPERIMENTAL
Intervention: Oxidized titanium implants (TiUnite)
Number of subjects: 12
Study: 12202088

Group type: EXPERIMENTAL
Intervention: Remifentanil (1.0 ng/ml effect site concentration)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study: 10469778

Group type: EXPERIMENTAL
Intervention: Red cell transfusions based on symptom-based guidelines (Group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Red cell transfusions to maintain hematocrit above 40% (Group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 50
Study: 8901853

Group type: EXPERIMENTAL
Intervention: 30 mg beta-carotene and 25,000 IU retinyl palmitate (vitamin A) taken daily
Number of subjects: 18314
Study: 1906634

Group type: EXPERIMENTAL
Intervention: Lactic acid producing bacteria (Lactobacillus acidophilus and Bifidobacterium bifidum) with 500 mg ampicillin t.i.d. for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo with 500 mg ampicillin t.i.d. for 7 days
Number of subjects: 20
Study: 6319633

Group type: EXPERIMENTAL
Intervention: Stress Management Program (SMP) consisting of eight weekly one-hour sessions of relaxation response, imagery, and diaphragmatic breathing; caffeine intake reduction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 28944645

Group type: EXPERIMENTAL
Intervention: BCAA (9.6 g·day‐1) before exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: BCAA (9.6 g·day‐1) after exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (placebo before and after exercise)
Number of subjects: 15
Study: 26979433

Group type: EXPERIMENTAL
Intervention: Test 1 (sucrose:xylose = 10:1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Test 2 (sucrose:xylose = 15:1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Test 3 (sucrose:xylose = 20:1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (sucrose 50 g + deionized water 100 g)
Number of subjects: 75
Study: 24439796

Group type: EXPERIMENTAL
Intervention: Robot-assisted TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 60
Study: 22741171

Group type: EXPERIMENTAL
Intervention: Food-based intervention to optimize dietary vitamin E intake to 15 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no dietary advice)
Number of subjects: 43
Study: 20625129

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Assessment-only condition
Number of subjects: 89
Study: 17352867

Group type: EXPERIMENTAL
Intervention: Yisui Shengxue Granule (YSSXG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15378384

Group type: EXPERIMENTAL
Intervention: Lamellar keratotomy with an incision width of 6 mm and a radial length of 1.5 mm
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lamellar keratotomy
Number of subjects: 25
Study: 11892639

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with epinephrine 1:200 000
Number of subjects: 133

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 133
Study: 10201586

Group type: EXPERIMENTAL
Intervention: First eye surgery
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Second eye surgery
Number of subjects: 403
Study: 8643968

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2 combined with carboplatin (AUC 6)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2 combined with carboplatin (AUC 6)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Paclitaxel (various doses)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with carboplatin
Number of subjects: 41
Study: 2177610

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 90
Study: 481481

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (Group A)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Melphalan, cyclophosphamide, carmustine, and prednisone in alternating schedule (Group B)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Melphalan, cyclophosphamide, carmustine, and prednisone in concurrent schedule (Group C)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: All treatment groups (A, B, C)
Number of subjects: 364
Study: 31912156

Group type: EXPERIMENTAL
Intervention: iCRAFT
Number of subjects: 94

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 94
Study: 31131743

Group type: EXPERIMENTAL
Intervention: Long-duration treatment (300 hours) with applied technology and motor learning.
Number of subjects: 31
Study: 28333010

Group type: EXPERIMENTAL
Intervention: HF-WBI (42.56 Gy/16 fractions + 10-12.5 Gy/4-5 fx boost)
Number of subjects: 287

Group type: COMPARATOR
Intervention: CF-WBI (50 Gy/25 fx + 10-14 Gy/5-7 fx)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Patient-reported cosmesis
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Physician-reported cosmesis
Number of subjects: 287
Study: 25809877

Group type: EXPERIMENTAL
Intervention: tamsulosin 0.2 mg once daily
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg once daily
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: both tamsulosin and solifenacin
Number of subjects: 112

Group type: COMPARATOR
Intervention: control group (A)
Number of subjects: 112
Study: 24010993

Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV) dosing appropriate for most patients
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: High-risk CMV serostatus (donor positive/recipient negative)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin induction therapy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Higher mean tacrolimus trough concentration
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Creatinine clearance <60 mL/min
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Body weight >80 kg
Number of subjects: 187
Study: 21383557

Group type: EXPERIMENTAL
Intervention: Anal fistula plug
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mucosal advancement flap
Number of subjects: 60
Study: 19741042

Group type: EXPERIMENTAL
Intervention: Audio computer‐assisted self‐interviewing (ACASI)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Face‐to‐face interviewing (FTFI)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 910

Group type: COMPARATOR
Intervention: FTFI
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: PSA-positive participants
Number of subjects: 910
Study: 17826341

Group type: EXPERIMENTAL
Intervention: Idebenone (5 mg/kg, 15 mg/kg, and 45 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Idebenone (high-dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15036546

Group type: EXPERIMENTAL
Intervention: Low incentive condition (US$ 10 per test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High incentive condition (US$ 20 per test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral fluid test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hair testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine testing
Number of subjects: 0
Study: 11753789

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (l-OHP) plus 5-fluorouracil and leucovorin (5-FU/LV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil and leucovorin (5-FU/LV) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (l-OHP) in combination with 5-FU/LV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (l-OHP)
Number of subjects: 0
Study: 9735586

Group type: EXPERIMENTAL
Intervention: 10-session assertiveness training intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 20
Study: 9028308

Group type: EXPERIMENTAL
Intervention: G‐CSF (granulocyte colony‐stimulating factor) at a dosage of 5 micrograms/kg, starting the day after completion of the third cycle of chemotherapy.
Number of subjects: 0
Study: 1723773

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Increased medical attention and care
Number of subjects: 468
Study: 6752872

Group type: EXPERIMENTAL
Intervention: Pirprofen 600 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ketoprofen 300 mg/day
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 124
Study: 31800988

Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 1672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1672
Study: 27737436

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: CapeOx and lapatinib with PPIs
Number of subjects: 545

Group type: COMPARATOR
Intervention: No Proton Pump Inhibitors (PPIs)
Number of subjects: 545
Study: 25575253

Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 104
Study: 25175658

Group type: EXPERIMENTAL
Intervention: fine particle beclomethasone (HFA‐BDP; Qvar Autohaler)
Number of subjects: 66

Group type: COMPARATOR
Intervention: budesonide (DPI‐BUD; Pulmicort Turbohaler)
Number of subjects: 66
Study: 22234397

Group type: EXPERIMENTAL
Intervention: Classic altitude training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Live High:Train Low (LHTL) altitude training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Race Control
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Classic and LHTL
Number of subjects: 26
Study: 19717347

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 413

Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Endovascular treatment with stent
Number of subjects: 413

Group type: COMPARATOR
Intervention: Endovascular treatment with balloon angioplasty
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Restenosis of 70% or more
Number of subjects: 413

Group type: COMPARATOR
Intervention: No restenosis of 70% or more
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Current smoking or history of smoking
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Moderate stenosis (50-69%) within 60 days after treatment
Number of subjects: 413
Study: 16891124

Group type: EXPERIMENTAL
Intervention: Awareness of impending movement
Number of subjects: 0

Group type: COMPARATOR
Intervention: No awareness of impending movement
Number of subjects: 0
Study: 15067694

Group type: EXPERIMENTAL
Intervention: Pulmonal THC (0.053 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous THC (0.053 mg/kg body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pulmonal Placebo
Number of subjects: 8
Study: 12417538

Group type: EXPERIMENTAL
Intervention: Roxithromycin (150 mg twice daily for 30 days)
Number of subjects: 272

Group type: COMPARATOR
Intervention: No therapy (control group for Cp-positive patients)
Number of subjects: 272

Group type: COMPARATOR
Intervention: No therapy (control group for Cp-negative patients)
Number of subjects: 272
Study: 9167520

Group type: EXPERIMENTAL
Intervention: Right lateral prefrontal repetitive transcranial magnetic stimulation (80% motor threshold, 20 Hz/2 seconds per minute for 20 minutes)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Left lateral prefrontal repetitive transcranial magnetic stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Midoccipital repetitive transcranial magnetic stimulation (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Right lateral prefrontal repetitive transcranial magnetic stimulation
Number of subjects: 12
Study: 1337337

Group type: EXPERIMENTAL
Intervention: GM-CSF administration starting one day after chemotherapy for 7-10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GM-CSF administration after high-dose chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GM-CSF administration after initial cycles of chemotherapy
Number of subjects: 0
Study: 3990156

Group type: EXPERIMENTAL
Intervention: Indomethacin for early closure of ductus arteriosus
Number of subjects: 27
Study: 30317146

Group type: EXPERIMENTAL
Intervention: Broccoli consumption (200 g of cooked broccoli and 20 g of raw daikon radish per day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Broccoli consumption
Number of subjects: 18
Study: 28780214

Group type: EXPERIMENTAL
Intervention: Successful External Cephalic Version (ECV)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Successful External Cephalic Version (ECV) in multiparous women
Number of subjects: 931

Group type: COMPARATOR
Intervention: Spontaneous Cephalic Version (SCV)
Number of subjects: 931
Study: 27139019

Group type: EXPERIMENTAL
Intervention: Ice pack therapy applied intermittently over the masseteric region post-surgery.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ice pack therapy (Control Group B).
Number of subjects: 0
Study: 24458443

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22922806

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration plus Squatting (WBV+S)
Number of subjects: 7
Study: 20431422

Group type: EXPERIMENTAL
Intervention: CRAI (continuous regional arterial infusion) with nafamostat mesylate 240 mg/d and imipenem 1 g/d for 5 days, followed by imipenem intravenously (0.5 g every 8 hours) for 9 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-CRAI group receiving imipenem (0.5 g every 8 hours) intravenously for 14 days
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CRAI group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-CRAI group
Number of subjects: 78
Study: 19089223

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment in Class II/1 malocclusion patients (group T)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Class I malocclusion patients (group C - control)
Number of subjects: 34
Study: 15634808

Group type: EXPERIMENTAL
Intervention: Perioperative inpatient intervention program involving patient education and providing a list of questions for the primary care physician.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group received a brochure describing methods for preventing falls.
Number of subjects: 80
Study: 11808967

Group type: EXPERIMENTAL
Intervention: COX-2-specific inhibitor and traditional NSAID therapy
Number of subjects: 3907
Study: 10521728

Group type: EXPERIMENTAL
Intervention: Endovaginal ultrasonographic assessment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Transperineal ultrasonographic assessment
Number of subjects: 102
Study: 7853952

Group type: EXPERIMENTAL
Intervention: 5000 IU unfractionated heparin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2000 anti-Xa IU low-molecular-weight heparin
Number of subjects: 39

Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 39
Study: 1992028

Group type: EXPERIMENTAL
Intervention: 1073 MBq iodine-131
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 3700 MBq iodine-131
Number of subjects: 63
Study: 6344270

Group type: EXPERIMENTAL
Intervention: Praziquantel (Biltricide; Bayer‐Miles) at a dosage of 40 mg/kg body weight
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group not mentioned
Number of subjects: 137
Study: 29431028

Group type: EXPERIMENTAL
Intervention: Kindergartens with expenditures for food and beverages included in parental fees
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Kindergartens where parents paid a monthly fee of 251 NOK or more
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Kindergartens where employees paid a monthly fee to eat at work
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Kindergartens with written guidelines for food and beverages offered
Number of subjects: 73
Study: 30303900

Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study: 27143871

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,800 mg twice daily for 8 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 51
Study: 24495355

Group type: EXPERIMENTAL
Intervention: Ginkgo Synergy(®) plus Choline
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: OPC Synergy(®) plus Catalyn(®)
Number of subjects: 97
Study: 22104034

Group type: EXPERIMENTAL
Intervention: Baseline (0 months)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Follow-up (6 months)
Number of subjects: 3
Study: 20457582

Group type: COMPARATOR
Intervention: RPE group (Hyrax screws activated every 12 hours for 1 week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: A/D-RPE group (Hyrax screws activated every 12 hours for 1 week, then deactivated every 12 hours for 1 week, followed by activation and deactivation for 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (RPE and A/D-RPE)
Number of subjects: 30
Study: 17714055

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) doses of 200-1080 microg in Study 1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) doses of 270-1300 microg in Study 2
Number of subjects: 70
Study: 16236802

Group type: COMPARATOR
Intervention: 40% CNI reduction plus mycophenolate mofetil (group 1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Immediate CNI withdrawal and rapamycin introduction (group 2)
Number of subjects: 84
Study: 12404691

Group type: EXPERIMENTAL
Intervention: Alcohol 0.5 g/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alcohol 0.3 g/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9834924

Group type: EXPERIMENTAL
Intervention: Enteral formula enriched with arginine, omega‐3 fatty acids, and RNA administered 7 days before and 7 days after surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Same diet but only 7 days after surgery
Number of subjects: 30
Study: 8129116

Group type: EXPERIMENTAL
Intervention: Early Mobilization Group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Immobilization Group
Number of subjects: 82
Study: 2659296

Group type: EXPERIMENTAL
Intervention: aztreonam + clindamycin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: tobramycin + clindamycin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: amikacin + mezlocillin
Number of subjects: 110